Dr. Raje on Current CAR T-Cell Therapies in Multiple Myeloma

Video

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses current CAR T-cell therapies in multiple myeloma.

Two CAR T-cell therapies are currently FDA approved, including idecabtagene vicleucel (ide-cel; Abecma), which was approved in March 2021 for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, Raje explains. In February 2022, ciltacabtagene autoleucel (cilta-cel; Carvykti) received approval for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy, Raje adds.

The indications for cilta-cel and ide-cel are for patients who have been exposed to a majority of treatment options, including lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), and an anti-CD38 monoclonal antibody, Raje concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD